TABLE 1.
Antibody response to RAP1 in the Daraweesh cohort
| Antigen | Antibody response by
season [no. positive/ no. total (%)] for
individualsa
|
|||||
|---|---|---|---|---|---|---|
| With clinically documented
malarial infection
|
Without clinical malaria
|
|||||
| 1992–1993 | 1993–1994 | 1994–1995 | 1992–1993 | 1993–1994 | 1994–1995 | |
| C1 | 3/13 (23) | 7/23 (30) | 10/30 (33) | 1/39 (3) | 1/27 (4) | 1/21 (5) |
| C2 | 5/13 (38) | 7/23 (30) | 9/30 (30) | 1/39 (3) | 0/27 (0) | 0/21 (0) |
| P2 | 5/13 (38) | 9/23 (39) | 9/30 (30) | 2/39 (5) | 1/27 (4) | 1/21 (5) |
| P3 | 5/13 (28) | 9/23 (39) | 9/30 (30) | 2/39 (5) | 1/27 (4) | 1/21 (5) |
| P4 | 5/13 (38) | 9/23 (39) | 9/30 (30) | 2/39 (5) | 1/27 (4) | 1/21 (5) |
| P5 | 5/13 (38) | 9/23 (39) | 9/30 (30) | 1/39 (3) | 1/27 (4) | 0/21 (0) |
a
Response was defined as a fourfold or higher increase in antibody level from a level detected in a pretransmission sample (September) to a level in an acute-malaria and/or posttransmission sample (January). Analysis was performed for those individuals with pre- and posttransmission season samples.